All News Zhejiang Ausun Pharmaceutical Co., Ltd.

Equities

603229

CNE100002XK2

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 25/04/2024 BST			5-day change	1st Jan Change
10.49 ^CNY	+0.87%		+9.84%	-20.59%

04-26	Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-26	Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-26	CI
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23	CI
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	29/08/23	CI
Zhejiang Qizheng Pharmaceutical Co., Ltd. announced that it has received CNY 20 million in funding from Zhejiang Ausun Pharmaceutical Co., Ltd.	08/05/23	CI
Ausun Pharma's Unit Passes Regulatory Inspection	08/05/23	MT
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23	CI
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	27/04/23	CI
Zhejiang Qizheng Pharmaceutical Co., Ltd. announced that it expects to receive CNY 20 million in funding from Zhejiang Ausun Pharmaceutical Co., Ltd.	25/04/23	CI
Zhejiang Ausun Pharma Sees Up to 70% Jump in 2022 Profit; Shares Rose 4%	19/01/23	MT
Zhejiang Ausun Pharma Gets Regulatory Nod to Market Azvudine	17/01/23	MT
Zhejiang Ausun Pharmaceutical Co., Ltd. announced that it has received CNY 484.90308 million in funding from Gongqingcheng Shengheng Investment Management Co., Ltd., Shanghai Panjing Investment Management Center (Limited Partnership), Taizhou Financial Holding Asset Management Co., Ltd., and other investors	16/01/23	CI
Marvel Biosciences Completes Manufacturing Milestone Ahead of Phase 1 Trials Targeting Alzheimer's Disease, Depression	06/01/23	MT
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	30/10/22	CI
Zhejiang Ausun Pharmaceutical Co., Ltd.(XSSC:603229) added to S&P Global BMI Index	19/09/22	CI
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	29/08/22	CI
Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study	11/07/22	MT
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	19/04/22	CI
Zhejiang Ausun Pharmaceutical Co., Ltd. announced that it expects to receive CNY 500 million in funding	07/03/22	CI
Zhejiang Ausun Pharmaceutical Co., Ltd. announced that it expects to receive CNY 500 million in funding from Gongqingcheng Shengheng Investment Management Co., Ltd., Shanghai Panjing Investment Management Center (Limited Partnership), Taizhou Financial Holding Asset Management Co., Ltd.	07/03/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Zhejiang Ausun Pharmaceutical Co., Ltd.

Equities

603229

CNE100002XK2

All News

Filters